AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17243700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangerine sauce (150 g containing 15 g of corn oil, 13 mg of lycopene)
Number of subjects: 12
Study 17243700 — intervention group
Group type: EXPERIMENTAL
Intervention: High-beta-carotene sauce (150 g containing 15 g of corn oil, 17 mg of total beta-carotene, 4 mg of lycopene)
Number of subjects: 12
Study 14722172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 2 micro g kg(‐1)
Number of subjects: 46
Study 14722172 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal clonidine 2 micro g kg(‐1)
Number of subjects: 46
Study 11560737 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration
Number of subjects: 0
Study 11560737 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0
Study 11560737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed methods evaluations
Number of subjects: 0
Study 9763070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Number of subjects: 537
Study 9763070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 537
Study 7844427 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole
Number of subjects: 415
Study 7844427 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 415
Study 7844427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole
Number of subjects: 415
Study 7844427 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 415
Study 3287973 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefotetan as a single prophylactic dose
Number of subjects: 260
Study 3287973 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefotetan as a single dose
Number of subjects: 260
Study 3287973 — intervention group
Group type: COMPARATOR
Intervention: 2 g cefoxitin every 6 hours for a maximum of 4 doses
Number of subjects: 260
Study 30294873 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI) through the Pediatric Appropriate Use of Echocardiography (PAUSE) study
Number of subjects: 7781
Study 30294873 — intervention group
Group type: COMPARATOR
Intervention: Post-Educational Intervention (post-EI)
Number of subjects: 7781
Study 30294873 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational Intervention (EI)
Number of subjects: 7781
Study 28162887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA)
Number of subjects: 102
Study 28162887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26233827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine administration
Number of subjects: 20
Study 26233827 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 20
Study 26233827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-test values of heart rate, blood pressure, Visual Analogue Scale for fear or discomfort
Number of subjects: 20
Study 24244339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine (10^9, 10^10, 5X10^10, 10^11 vp) administered on days 0, 28, and 84
Number of subjects: 48
Study 24244339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad35.CS.01 vaccine
Number of subjects: 48
Study 24244339 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 48
Study 20580251 — intervention group
Group type: EXPERIMENTAL
Intervention: IDON plus resistance exercise (NS + EX)
Number of subjects: 32
Study 20580251 — intervention group
Group type: COMPARATOR
Intervention: IDON (NS) alone
Number of subjects: 32
Study 20580251 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 32
Study 18347653 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary isometric activations (MVIA) in LBP group
Number of subjects: 20
Study 18347653 — intervention group
Group type: COMPARATOR
Intervention: MVIA force, right and left ULES, and LLES EMG in control group
Number of subjects: 20
Study 18347653 — intervention group
Group type: EXPERIMENTAL
Intervention: MVIA force, right and left ULES, and LLES EMG in LBP group
Number of subjects: 20
Study 18347653 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG of biceps femoris (BF) in both groups
Number of subjects: 20
Study 18347653 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance at 100% HAT in LBP group
Number of subjects: 20
Study 18347653 — intervention group
Group type: COMPARATOR
Intervention: Higher percentages of HAT in control group
Number of subjects: 20
Study 17168161 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation
Number of subjects: 692
Study 17168161 — intervention group
Group type: EXPERIMENTAL
Intervention: Various brain electrostimulation procedures
Number of subjects: 692
Study 17168161 — intervention group
Group type: EXPERIMENTAL
Intervention: Different surgical techniques
Number of subjects: 692
Study 17168161 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 692
Study 14748475 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate treatment (200 mg/day for 2 weeks per 3 months)
Number of subjects: 50
Study 14748475 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate treatment (5 mg/day)
Number of subjects: 50
Study 11040231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pima Indians
Number of subjects: 119
Study 11040231 — intervention group
Group type: COMPARATOR
Intervention: Whites
Number of subjects: 119
Study 11040231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ethnic groups
Number of subjects: 119
Study 8642881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal nasal ventilation (NNV) using a bilevel positive airway pressure (PAP) device set to deliver an inspiratory pressure of 10 cm H2O and a minimal expiratory pressure of 2 cm H2O.
Number of subjects: 13
Study 8642881 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment using a bilevel positive airway pressure (PAP) device set to deliver an inspiratory pressure of 0 cm H2O and a minimal expiratory pressure of 2 cm H2O.
Number of subjects: 13
Study 8642881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal nasal ventilation (NNV)
Number of subjects: 13
Study 8642881 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 13
Study 8642881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal nasal ventilation (NNV) and Sham treatment
Number of subjects: 13
Study 1505287 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 300 mg at night (2200 hr)
Number of subjects: 15
Study 1505287 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg three times a day (1800, 0800 and 1200 hr)
Number of subjects: 15
Study 1505287 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study 6098223 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand lotion containing 2% glutaric acid
Number of subjects: 0
Study 6098223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30561129 — intervention group
Group type: EXPERIMENTAL
Intervention: Xerostom® toothpaste and mouthwash (used 3 times/day for 28 days)
Number of subjects: 24
Study 30561129 — intervention group
Group type: COMPARATOR
Intervention: Control products (used 3 times/day for 28 days)
Number of subjects: 24
Study 31191847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal incision repair
Number of subjects: 1028
Study 31191847 — intervention group
Group type: COMPARATOR
Intervention: Uterine exteriorization for incision repair
Number of subjects: 1028
Study 26690292 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management intervention (escalating monetary vouchers for smoking reduction targets)
Number of subjects: 118
Study 26690292 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management intervention
Number of subjects: 118
Study 24570280 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients with sCJD
Number of subjects: 73
Study 24570280 — intervention group
Group type: COMPARATOR
Intervention: Younger patients with sCJD
Number of subjects: 73
Study 22481650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetal biomembrane
Number of subjects: 21
Study 22481650 — intervention group
Group type: COMPARATOR
Intervention: Fibrase(®) (CONTROL)
Number of subjects: 21
Study 21212672 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 21212672 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 17324127 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated cutting needles
Number of subjects: 502
Study 17324127 — intervention group
Group type: COMPARATOR
Intervention: Aspiration technique
Number of subjects: 502
Study 16310435 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 2708
Study 16310435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2708
Study 16310435 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 2708
Study 11383587 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study 11383587 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional food‐borne beneficial bacteria
Number of subjects: 0
Study 11383587 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotechnology‐based products
Number of subjects: 0
Study 9822501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 as a 0.5-mg intracervical gel (Prepidil) with immediate oxytocin
Number of subjects: 70
Study 9822501 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 as a 10-mg controlled-release vaginal insert (Cervidil) with delayed oxytocin
Number of subjects: 70
Study 7927956 — intervention group
Group type: COMPARATOR
Intervention: Ramipril 2.5 mg
Number of subjects: 624
Study 7927956 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 624
Study 7927956 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril 2.5 mg plus Hydrochlorothiazide 12.5 mg
Number of subjects: 624
Study 2913132 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol repeat‐action tablets with a high fat content breakfast
Number of subjects: 12
Study 2913132 — intervention group
Group type: COMPARATOR
Intervention: Albuterol repeat‐action tablets without food
Number of subjects: 12
Study 163848 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin aerosol (2.5 mg/kg body wt/day in six divided doses)
Number of subjects: 744
Study 163848 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 744
Study 163848 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin aerosol
Number of subjects: 744
Study 395129 — intervention group
Group type: EXPERIMENTAL
Intervention: Lofepramine
Number of subjects: 22
Study 395129 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 22
Study 31443716 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 for 3 months
Number of subjects: 288
Study 31443716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 31443716 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85 for 6 months
Number of subjects: 288
Study 31443716 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-85
Number of subjects: 288
Study 28537001 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium/olodaterol fixed‐dose combination (FDC)
Number of subjects: 180
Study 28537001 — intervention group
Group type: COMPARATOR
Intervention: tiotropium
Number of subjects: 180
Study 27503566 — intervention group
Group type: EXPERIMENTAL
Intervention: TRPV1 agonist (capsaicin 1 × 10(−5) M)
Number of subjects: 38
Study 27503566 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous sensory electrical stimulation (TSES) (Intelect VitalStim, biphasic pulses, 300 μs, 80 Hz)
Number of subjects: 38
Study 27503566 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TRPV1 and TSES)
Number of subjects: 38
Study 25171815 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim Milk (SM)
Number of subjects: 38
Study 25171815 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate/Electrolyte Solution (CES)
Number of subjects: 38
Study 25171815 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 38
Study 22996098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training (group 1, n=103)
Number of subjects: 203
Study 22996098 — intervention group
Group type: COMPARATOR
Intervention: Demonstration training (group 2, n=100)
Number of subjects: 203
Study 22996098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training (group 1, n=67) after 72 hours
Number of subjects: 203
Study 22996098 — intervention group
Group type: COMPARATOR
Intervention: Demonstration training (group 2, n=60) after 72 hours
Number of subjects: 203
Study 22996098 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-on training (group 1)
Number of subjects: 203
Study 22996098 — intervention group
Group type: COMPARATOR
Intervention: Demonstration training (group 2)
Number of subjects: 203
Study 19788472 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 121
Study 19788472 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 121
Study 19788472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 17150023 — intervention group
Group type: EXPERIMENTAL
Intervention: ID-KLH vaccine plus granulocyte-macrophage colony-stimulating factor
Number of subjects: 0
Study 17150023 — intervention group
Group type: EXPERIMENTAL
Intervention: BiovaxID plus granulocyte-macrophage colony-stimulating factor vaccination
Number of subjects: 0
Study 15116260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (HMG CoA reductase inhibitor)
Number of subjects: 759
Study 15116260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 759
Study 11603956 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper dose of 2 mg Cu/L
Number of subjects: 179
Study 11603956 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper dose of 4 mg Cu/L
Number of subjects: 179
Study 11603956 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper dose of 6 mg Cu/L
Number of subjects: 179
Study 11603956 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper dose of 8 mg Cu/L
Number of subjects: 179
Study 11603956 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 mg Cu/L)
Number of subjects: 179
Study 9557622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy for ALL
Number of subjects: 16
Study 9557622 — intervention group
Group type: COMPARATOR
Intervention: Influenza virus vaccine (1996-1997)
Number of subjects: 16
Study 9557622 — intervention group
Group type: EXPERIMENTAL
Intervention: B/T lymphocyte ratio during chemotherapy
Number of subjects: 16
Study 9557622 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum immunoglobulin levels
Number of subjects: 16
Study 11271343 — intervention group
Group type: COMPARATOR
Intervention: Long-term steroid therapy (0.1 mg/kg per day)
Number of subjects: 46
Study 11271343 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid withdrawal
Number of subjects: 46
Study 2651949 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (200 mg IV every 6 hours for 4 days)
Number of subjects: 23
Study 2651949 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (200 mg IV every 6 hours) with dopamine (1 microgram/kg/min for 4 days)
Number of subjects: 23
Study 1124717 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg/day
Number of subjects: 19
Study 1124717 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 19
Study 1124717 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (increasing doses)
Number of subjects: 19
Study 31537327 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with a reduction in LVESV >35% in patients with LBBB
Number of subjects: 1436
Study 31537327 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D with a reduction in LVESV ≤35% in patients with LBBB
Number of subjects: 1436
Study 31537327 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D in patients without LBBB
Number of subjects: 1436
Study 31537327 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D patients without LBBB with least reverse remodeling (quartile 1)
Number of subjects: 1436
Study 28757104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar electric energy (group A)
Number of subjects: 40
Study 28757104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic advanced energy (Harmonic®) (group B)
Number of subjects: 40
Study 26545263 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in social stress when with classmates, during weekdays, and in the morning.
Number of subjects: 278
Study 26545263 — intervention group
Group type: EXPERIMENTAL
Intervention: Loneliness as a moderating factor.
Number of subjects: 278
Study 23639514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexmedetomidine (DEX, 0.5 μg/kg; n = 18)
Number of subjects: 37
Study 23639514 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (CON; n = 19)
Number of subjects: 37
Study 21286241 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg nightly (n = 17)
Number of subjects: 33
Study 21286241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study 19706631 — intervention group
Group type: EXPERIMENTAL
Intervention: sub-Tenon's block
Number of subjects: 200
Study 19706631 — intervention group
Group type: COMPARATOR
Intervention: i.v. fentanyl
Number of subjects: 200
Study 19706631 — intervention group
Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 200
Study 17061999 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg plus full-dose cyclosporine (FDC)
Number of subjects: 668
Study 17061999 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 5.0 mg plus reduced-dose cyclosporine (RDC)
Number of subjects: 668
Study 17061999 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) plus full-dose cyclosporine (FDC)
Number of subjects: 668
Study 17061999 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 2.5 mg
Number of subjects: 668
Study 17061999 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720 5.0 mg
Number of subjects: 668
Study 17061999 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 668
Study 17061999 — intervention group
Group type: EXPERIMENTAL
Intervention: FTY720
Number of subjects: 668
Study 15055565 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2% solution
Number of subjects: 0
Study 15055565 — intervention group
Group type: COMPARATOR
Intervention: Patanol (olopatadine 0.1%)
Number of subjects: 0
Study 10933918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic liposome (EDMPC cholesterol) complexed with hCFTR cDNA
Number of subjects: 11
Study 10933918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8833678 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions
Number of subjects: 30
Study 8833678 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 30
Study 8833678 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment approaches
Number of subjects: 30
Study 1330437 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 6100
Study 1330437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6100
Study 2414023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum
Number of subjects: 116
Study 2414023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 116
Study 2414023 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum and Bleomycin (combined treatment)
Number of subjects: 116
Study 2414023 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 116
Study 29158011 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended intermittent letrozole (2.5 mg/day orally for 9 months followed by a 3-month break in years 1-4 and then 2.5 mg/day during all 12 months of year 5)
Number of subjects: 4851
Study 29158011 — intervention group
Group type: COMPARATOR
Intervention: Continuous letrozole (2.5 mg/day orally for 5 years)
Number of subjects: 4851
Study 29158011 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intermittent and continuous letrozole)
Number of subjects: 4851
Study 28453454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hyaluronate and tramadol injection
Number of subjects: 30
Study 28453454 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular hyaluronate injection alone
Number of subjects: 30
Study 25592003 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine
Number of subjects: 0
Study 25592003 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine
Number of subjects: 0
Study 23249571 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE-covered stents
Number of subjects: 37
Study 23249571 — intervention group
Group type: COMPARATOR
Intervention: Uncovered stents
Number of subjects: 37
Study 22115190 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized ventilation
Number of subjects: 70
Study 22115190 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation
Number of subjects: 70
Study 18328348 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG) 4 mg/d (increased to 8 mg/d after 6 months) plus glibenclamide
Number of subjects: 89
Study 18328348 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus glibenclamide
Number of subjects: 89
Study 17139601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostanoids, endothelin receptor antagonists, or phosphodiesterase 5 inhibitors
Number of subjects: 0
Study 17139601 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 17139601 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiroergometry and Doppler stress echocardiography
Number of subjects: 0
Study 17139601 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of underlying disease
Number of subjects: 0
Study 14971794 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine 0.2 mg kg(‐1) i.v.
Number of subjects: 60
Study 14971794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60